Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Azam Ghafoor

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Avicenna Journal of Medicine|April 25, 2014
Renal confined sarcoidosis: Natural history and diagnostic challengeAzam Ghafoor, Akram Almakki
Cancer|February 23, 2021
Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapiesZishuo I Hu, Azam Ghafoor, Manjistha Sengupta, et al.
European Journal of Haematology|December 8, 2021
Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disordersOmotola O Olasupo, Craig Haddix, Charles Nakar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 10, 2021
Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 MutationsZishuo I Hu, Markku Miettinen, Martha Quezado, et al.
JTO Clinical and Research Reports|October 18, 2021
Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in <i>BAP1</i> GeneAzam Ghafoor, Idrees Mian, Cathy Wagner, et al.
Science Translational Medicine|July 3, 2020
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor modelsQun Jiang, Azam Ghafoor, Idrees Mian, et al.
JTO Clinical and Research Reports|September 29, 2025
Local Ablative Therapy Followed by Osimertinib Rechallenge in Oligoprogressive, EGFR-Mutated NSCLC: A Phase 2 StudyAzam Ghafoor, Nitin Roper, Chul Kim, et al.
CVIR Oncology|December 22, 2025
Mapping drug distribution using CT imaging following direct tissue injection in ex vivo liver: informing clinical implementationRobert Morhard, Michal Mauda-Havakuk, Jose F Delgado, et al.
Biorxiv : the Preprint Server for Biology|September 19, 2025
HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-Driven Small Cell Lung CancerAzam Ghafoor, Linying Zhu, Zoe Weaver Ohler, et al.
JAMA Dermatology|May 17, 2024
Multiple Onychopapillomas and BAP1 Tumor Predisposition SyndromeAlexandra Lebensohn, Azam Ghafoor, Luke Bloomquist, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Avicenna Journal of Medicine|April 25, 2014
Renal confined sarcoidosis: Natural history and diagnostic challengeAzam Ghafoor, Akram Almakki
Cancer|February 23, 2021
Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapiesZishuo I Hu, Azam Ghafoor, Manjistha Sengupta, et al.
European Journal of Haematology|December 8, 2021
Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disordersOmotola O Olasupo, Craig Haddix, Charles Nakar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 10, 2021
Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 MutationsZishuo I Hu, Markku Miettinen, Martha Quezado, et al.
JTO Clinical and Research Reports|October 18, 2021
Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in <i>BAP1</i> GeneAzam Ghafoor, Idrees Mian, Cathy Wagner, et al.
Science Translational Medicine|July 3, 2020
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor modelsQun Jiang, Azam Ghafoor, Idrees Mian, et al.
JTO Clinical and Research Reports|September 29, 2025
Local Ablative Therapy Followed by Osimertinib Rechallenge in Oligoprogressive, EGFR-Mutated NSCLC: A Phase 2 StudyAzam Ghafoor, Nitin Roper, Chul Kim, et al.
CVIR Oncology|December 22, 2025
Mapping drug distribution using CT imaging following direct tissue injection in ex vivo liver: informing clinical implementationRobert Morhard, Michal Mauda-Havakuk, Jose F Delgado, et al.
Biorxiv : the Preprint Server for Biology|September 19, 2025
HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-Driven Small Cell Lung CancerAzam Ghafoor, Linying Zhu, Zoe Weaver Ohler, et al.
JAMA Dermatology|May 17, 2024
Multiple Onychopapillomas and BAP1 Tumor Predisposition SyndromeAlexandra Lebensohn, Azam Ghafoor, Luke Bloomquist, et al.
Pageof 2